King Pharmaceuticals, Inc. (KG) and partner Acura Pharmaceuticals, Inc. (ACUR) recently announced the submission of a new drug application (NDA) for their opioid candidate, Acurox. The companies are seeking US Food and Drug Administration (FDA) approval for the use of Acurox (without niacin) for providing relief from moderate to severe pain.
Acurox has been developed using Acura’s Aversion technology. King Pharma is seeking priority review for the candidate.
King Pharma and Acura had also submitted a new drug application seeking approval for Acurox (with niacin) for which the companies received a Complete Response Letter (CRL) on June 30, 2009. Based on discussions with the FDA, King Pharma and Acura submitted the NDA to an FDA advisory panel. However, earlier this year, the FDA panel voted that they did not have sufficient evidence to support the approval of Acurox for the treatment of moderate to severe pain. King Pharma intends to provide an update on the regulatory status of its Acurox (with niacin) tablet shortly.
King Pharma’s agreement with Acura relates to the licensing, development, and commercialization of immediate release (IR) pain medicines utilizing Acura’s Aversion (abuse-deterrent) technology. The agreement covers the US, Canada, and Mexico. The companies will initially focus on the development and commercialization of four immediate release opioid analgesic products including Acurox, Vycavert and Acuracet
Neutral on King Pharma
We currently have a ‘Neutral’ recommendation on King Pharma, which is supported by a Zacks #3 Rank (short-term “Hold” rating). In October 2010, the company entered into an agreement with Pfizer (PFE) whereby Pfizer will acquire King Pharma for $14.25 per share.
The offer price represents a 40% premium on King Pharma’s closing price as of October 11, 2010. The Boards of both companies have approved the deal, which is scheduled to close later this year/early next year.
This is a sample profile field. Vitalstocks is the operating company for Stockbloghub. This will place the picture of the author or company in the profile. Here is another extra line of information.
Powered by Facebook Comments